objectivesw
sought
determin
whether
circul
solubl
angiotensinconvert
enzym
increas
plasma
patient
heart
failur
hf
backgroundangiotensinconvert
enzym
integr
membran
protein
antagon
action
angiotensin
ii
prevent
develop
hf
anim
model
howev
need
invas
cardiac
tissu
sampl
littl
known
whether
involv
pathophysiolog
hf
human
methodsw
develop
sensit
specif
assay
measur
activ
human
plasma
screen
heterogen
group
patient
suspect
clinic
hf
resultsincreas
plasma
activ
strongli
correl
clinic
diagnosi
hf
p
worsen
left
ventricular
eject
fraction
p
increas
btype
natriuret
peptid
level
p
similar
btype
natriuret
peptid
activ
reflect
sever
hf
increas
level
associ
worsen
new
york
heart
associ
function
class
p
associ
independ
diseas
state
medic
use
found
activ
increas
patient
ischem
nonischem
cardiomyopathi
also
patient
clinic
hf
preserv
left
ventricular
eject
fraction
conclusionssolubl
activ
increas
patient
hf
correl
diseas
sever
suggest
cardioprotect
arm
reninangiotensinaldosteron
system
activ
hf
paramet
includ
limit
clinic
model
includ
age
gender
bnp
ngml
lvef
creatinin
paramet
includ
full
model
includ
limit
model
addit
use
loop
diuret
aldosteron
antagonist
ace
inhibitor
arb
presenc
atrial
fibril
diabet
mellitu
hypertens
coronari
arteri
diseas
ci
confid
interv
odd
ratio
sace
solubl
angiotensinconvert
enzym
abbrevi
tabl
j
coll
cardiol
although
pathophysiolog
heart
failur
hf
complex
import
final
common
pathway
involv
activ
reninangiotensinaldosteron
system
raa
angiotensinconvert
enzym
ace
mediat
cleavag
angiotensin
ang
ang
ii
peptid
act
downstream
specif
angiotensin
type
receptor
togeth
import
target
modern
hf
therapeut
angiotensinconvert
enzym
recent
discov
homolog
contrast
member
raa
seemingli
protect
hf
integr
membran
carboxypeptidas
remov
termin
aminoacid
ang
ii
result
product
biolog
activ
peptid
ang
antagon
effect
ang
ii
activ
ma
receptor
mice
defici
increas
ang
ii
level
sever
cardiac
contractil
defect
revers
genet
delet
ace
intracardiac
overexpress
prevent
ang
iiinduc
hypertens
cardiac
fibrosi
implic
direct
vivo
cardioprotect
role
addit
suggest
possibl
therapeut
util
gene
express
increas
tissu
samplesfrom
patient
left
ventricular
dysfunct
tradit
thought
tissu
bound
result
need
invas
cardiac
tissu
sampl
limit
addit
clinic
studi
herein
examin
feasibl
detect
solubl
angiotensinconvert
enzym
activ
human
plasma
hypothes
endogen
regulatori
arm
raa
measur
would
increas
patient
hf
quench
fluoresc
substrat
protocol
perform
previous
describ
modif
human
plasma
bioreclam
hicksvil
new
york
patient
plasma
sampl
dilut
ratio
enzym
buffer
moll
mmoll
trishcl
mmoll
zncl
ph
presenc
proteas
inhibitor
includ
captopril
amastatin
bestatin
sigma
chemic
co
st
loui
missouri
zproprolin
biomol
intern
lp
plymouth
meet
pennsylvania
sampl
incub
quench
fluoresc
substrat
dilut
enzym
buffer
final
concentr
maxim
fluoresc
spectramax
geminix
molecular
devic
wokingham
unit
kingdom
determin
experiment
nm
nm
use
cutoff
filter
specif
determin
preincub
plasma
min
either
specif
human
inhibitor
phoenix
pharmaceut
burlingam
california
polyclon
antibodi
control
polyclon
antibodi
r
system
inc
minneapoli
minnesota
patient
plasma
activ
determin
h
h
baselin
valu
normal
recombin
standard
curv
r
system
intraassay
variabl
interassay
variabl
subsequ
use
assay
patient
sampl
studi
receiv
institut
review
board
approv
plasma
sampl
n
obtain
subject
suspect
clinic
hf
measur
btype
natriuret
peptid
bnp
advia
assay
siemen
corpor
new
york
new
york
cleveland
clinic
march
august
exclud
patient
congenit
heart
diseas
acut
coronari
syndrom
postop
set
manual
chart
review
perform
physician
blind
analysi
adjud
presenc
hf
sever
clinic
echocardiograph
within
day
sampl
isol
includ
left
ventricular
eject
fraction
lvef
assess
use
biplan
simpson
rule
biochem
characterist
demograph
determin
databas
closur
blind
sampl
analysi
univari
analys
conduct
student
test
chisquar
test
group
analysi
varianc
among
interquartil
rang
variou
clinic
paramet
logist
regress
analysi
perform
assess
confound
variabl
stepwis
analysi
also
perform
model
use
probabl
enter
leav
yield
result
similar
present
miss
data
left
unassign
analysi
exceed
n
variabl
statist
analysi
perform
jmp
sa
institut
cari
north
carolina
p
valu
consid
signific
specif
inhibitor
inhibit
recombin
activ
dosedepend
fashion
fig
polyclon
antibodi
inhibit
activ
human
plasma
sampl
demonstr
observ
increas
fluoresc
attribut
specif
activ
fig
solubl
angiotensinconvert
enzym
activ
inhibit
commerci
avail
plasma
indic
ubiquit
basal
express
ngml
studi
cohort
clinic
diagnosi
hf
case
show
biochem
clinic
evid
hf
control
tabl
plasma
activ
stratifi
quartil
increas
activ
strongli
correl
diagnosi
hf
irrespect
etiolog
associ
diseas
state
tabl
odd
ratio
predict
hf
valu
fourth
quartil
p
fisher
exact
test
solubl
activ
also
associ
worsen
lvef
increas
bnp
level
use
loop
diuret
tabl
associ
activ
aldosteron
antagonist
clearli
demonstr
use
direct
comparison
ngml
confid
interv
absenc
vs
presenc
aldosteron
antagonist
vs
p
analysi
varianc
logist
regress
analysi
activ
independ
associ
presenc
hf
tabl
greater
activ
associ
worsen
new
york
heart
associ
nyha
function
class
fig
use
logist
regress
analysi
found
activ
independ
associ
increas
nyha
function
class
p
logtransform
bnp
p
invers
associ
lvef
p
aldosteron
antagonist
class
medic
found
independ
associ
plasma
activ
chisquar
p
understand
relationship
cardiac
cell
growth
fibrosi
remodel
may
help
us
better
understand
protect
raa
pathway
involv
hf
despit
mani
eleg
anim
studi
rel
pauciti
knowledg
whether
physiolog
relev
human
herein
present
import
observ
human
hf
activ
readili
measur
heterogen
patient
popul
activ
elev
human
hf
activ
correl
independ
worsen
diseas
sever
defin
lvef
nyha
function
class
one
intrigu
question
studi
rais
role
play
hf
progress
similar
counterpart
ace
integr
membran
protein
signal
peptid
ntermin
transmembran
domain
presenc
circul
plasma
indic
either
caus
effect
adapt
maladapt
physiolog
process
oper
human
hf
unlik
ace
known
cleavag
membran
solubl
form
part
depend
tumor
necrosi
convertas
proteas
upregul
hf
upregul
proinflammatori
cytokin
activ
proteas
hf
long
implic
patholog
mechan
cardiac
remodel
therefor
cleavag
membran
may
due
upregul
patholog
proteas
result
rel
decreas
local
membran
level
cardiac
dysfunct
altern
cleavag
releas
membran
solubl
form
may
offer
compensatori
mechan
hf
angiotensin
short
halflif
releas
vascular
endothelium
may
serv
alter
system
ang
concentr
rel
peripher
balanc
demonstr
relationship
greater
level
activ
hf
data
give
us
insight
system
activ
endogen
counterregulatori
pathway
beyond
membranebound
confin
express
modul
varieti
mechan
aldosteron
decreas
transcript
nicotinamid
adenin
dinucleotid
phosphat
oxidasemedi
pathway
therefor
interest
observ
direct
correl
use
aldosteron
receptor
antagonist
greater
activ
consist
observ
increas
product
patient
treat
spironolacton
indic
potenti
mechan
benefici
effect
stimul
receptor
also
known
suppress
express
howev
unlik
anim
studi
patient
studi
expos
longterm
inhibit
raa
might
account
lack
associ
plasma
use
either
ace
inhibitor
ang
receptor
blocker
associ
plasma
activ
plasma
bnp
provid
object
valid
associ
system
releas
hf
sever
detect
activ
like
signifi
activ
counterregulatori
mechan
ultim
clinic
util
measur
activ
may
depend
abil
possibl
target
activ
ma
pathway
rather
improv
clinic
diagnosi
hf
acut
set
latter
task
plasma
bnp
test
well
valid
perform
data
support
investig
better
understand
clinic
util
signific
target
pathway
therapeut
intervent
use
specif
sensit
assay
solubl
activ
detect
human
plasma
increas
solubl
activ
associ
advanc
hf
quartil
plot
shown
oneway
analysi
varianc
p
number
patient
n
given
group
hf
heart
failur
nyha
new
york
heart
associ
solubl
angiotensinconvert
enzym
activ
